Circulation, 146, 657-672 Circulation : an official journal of the American Heart Association / ed.-in-chief Ephraim Donosco 146(9), 657-672 (2022). doi:10.1161/CIRCULATIONAHA.121.057807 Hagström, E, Steg, P G, Szarek, M, Bhatt, D L, Bittner, V A, Danchin, N, Diaz, R, Goodman, S G, Harrington, R A, Jukema, J W, Liberopoulos, E, Marx, N, McGinniss, J, Manvelian, G, Pordy, R, Scemama, M, White, H D, Zeiher, A M, Schwartz, G G, ODYSSEY OUTCOMES Investigators & Bøttcher, M 2022, ' Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab ', Circulation, vol. 146, no. 9, pp. 657-672 . https://doi.org/10.1161/CIRCULATIONAHA.121.057807 Circulation, vol 146, iss 9 Circulation, 146, 9, pp. 657-672 Circulation, Philadelphia : Lippincott Williams & Wilkins, 2022, vol. 146, iss. 9, p. 657-672 Circulation, 146(9), 657-672. LIPPINCOTT WILLIAMS & WILKINS
Journal of the American College of Cardiology, 78(5), 421-433. ELSEVIER SCIENCE INC Journal of The American College of Cardiology, New York : Elsevier Biomedical, 2021, vol. 78, no. 5, p. 421-433 Repositorio Universidad de Santander Universidad de Santander instacron:Universidad de Santander Schwartz, G G, Szarek, M, Bittner, V A, Diaz, R, Goodman, S G, Jukema, J W, Landmesser, U, López-Jaramillo, P, Manvelian, G, Pordy, R, Scemama, M, Sinnaeve, P, White, H D, Gabriel Steg, P, Gabriel Steg, P H, Bhatt, D L, Harrington, R A, Zeiher, A M, Tricoci, P, Roe, M T, Mahaffey, K W, Edelberg, J M, Hanotin, C, Lecorps, G, Moryusef, A, Sasiela, W J, Tamby, J F, Aylward, P E, Drexel, H, Sinnaeve, P, Dilic, M, Lopes, R D, Gotcheva, N N, Prieto, J C, Yong, H, Pećin, I, Reiner, Z, Clemmensen, P, Bang, L E, Hove, J D, Gislason, G, Larsen, J, Johansen, P, Jeppesen, J, Nielsen, P K, Hansen, O, Jensen, S A, Rosenberg, M, Andersen, D & ODYSSEY OUTCOMES Committees and Investigators 2021, ' Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol ', Journal of the American College of Cardiology, vol. 78, no. 5, pp. 421-433 . https://doi.org/10.1016/j.jacc.2021.04.102 Schwartz, G G, Szarek, M, Bittner, V A, Diaz, R, Goodman, S G, Jukema, J W, Landmesser, U, López-Jaramillo, P, Manvelian, G, Pordy, R, Scemama, M, Sinnaeve, P, White, H D, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2021, ' Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol ', Journal of the American College of Cardiology, vol. 78, no. 5, pp. 421-433 . https://doi.org/10.1016/j.jacc.2021.04.102 Journal of the American College of Cardiology, vol 78, iss 5
Lancet Diabetes & Endocrinology r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname The Lancet Diabetes & Endocrinology Volume 7 Issue 8 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tuñón, J, White, H D, Zeiher, A M, Schwartz, G G, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tuñón, J, White, H D, Zeiher, A M, Schwartz, G G, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Lancet diabetes & endocrinology ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tunon, J, White, H D, Zeiher, A M, Schwartz, G S, Steg, P G, Schwartz, G G, Steg, P G, ODYSSEY OUTCOMES Committees and Investigators, Clemmensen, P, Gislason, G, Nielsen, P K, Davidsen, F, Andersen, D, Jeppesen, J & Videbæk, L 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA Lancet Diabetes and Endocrinology, 7(8), 618-628. ELSEVIER SCIENCE INC
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid European Journal of Heart Failure ABACUS. Repositorio de Producción Científica Universidad Europea (UEM)